Anti-beta Catenin antibody [EP690Y],Abcam,AB68183

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

ICC/IF, Flow Cyt (Intra), WB

Platform ID

BAB537142721

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-beta Catenin antibody [EP690Y]
Cat. No.AB68183
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationICC/IF, Flow Cyt (Intra), WB
ClonalityMonoclonal
Clone NumberEP690Y
Concentration0.137 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Key downstream component of the canonical Wnt signaling pathway (PubMed : 17524503, PubMed : 18077326, PubMed : 18086858, PubMed : 18957423, PubMed : 21262353, PubMed : 22155184, PubMed : 22647378, PubMed : 22699938). In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome (PubMed : 17524503, PubMed : 18077326, PubMed : 18086858, PubMed : 18957423, PubMed : 21262353, PubMed : 22155184, PubMed : 22647378, PubMed : 22699938). In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes (PubMed : 17524503, PubMed : 18077326, PubMed : 18086858, PubMed : 18957423, PubMed : 21262353, PubMed : 22155184, PubMed : 22647378, PubMed : 22699938). Involved in the regulation of cell adhesion, as component of an E-cadherin : catenin adhesion complex (By similarity). Acts as a negative regulator of centrosome cohesion (PubMed : 18086858). Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization (PubMed : 21262353). Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2 (PubMed : 18957423). Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML (PubMed : 22155184). Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (By similarity). Involved in chondrocyte differentiation via interaction with SOX9 : SOX9-binding competes with the binding sites of TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling (By similarity). Acts as a positive regulator of odontoblast differentiation during mesenchymal tooth germ formation, via promoting the transcription of differentiation factors such as LEF1, BMP2 and BMP4 (By similarity). Activity is repressed in a MSX1-mediated manner at the bell stage of mesenchymal tooth germ formation which prevents premature differentiation of odontoblasts (By similarity). See full target information CTNNB1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.